Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer
April 05 2021 - 4:05PM
Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief
Medical Officer
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
company with expertise in protein dysregulation and a pipeline of
investigational therapeutics for rare peripheral amyloid and
neurodegenerative diseases, today announced the appointment of
Hideki Garren, MD, PhD, as Chief Medical Officer. Dr. Garren will
lead the clinical and medical organizations to advance Prothena’s
clinical pipeline.
“Hideki brings valuable experience and expertise
to our team as we look ahead towards transitioning to a fully
integrated research, development and commercial biotechnology
company,” said Gene Kinney, PhD, President and Chief Executive
Officer. “His experience leading several late-stage development
programs in neurology and rare disease indications through
registration and launch is particularly relevant as we advance our
pipeline of programs in these areas. We are delighted to welcome
him to the team as we prepare for our next stage of growth.”
“Prothena’s impressive scientific platform has
advanced a rich pipeline of potentially transformational
therapeutics, including several programs that have demonstrated
benefit on meaningful clinical endpoints in diseases with highly
significant unmet medical needs,” commented Dr. Garren. “I am
excited to join the company during this dynamic period of growth
and look forward to working as part of this exceptional team with a
rich scientific heritage.”
Dr. Garren joins Prothena from F. Hoffmann-La
Roche Ltd. (Roche) & Genentech Inc. where he was Vice
President, Global Head of Neuroimmunology, leading Roche’s
Neuroimmunology franchise team. A neurologist by training, Dr.
Garren was most recently responsible for the Phase 3 clinical
programs for Ocrevus for Multiple Sclerosis and Enspryng for
Neuromyelitis Optica Spectrum Disorder. Dr. Garren also held the
role of Executive Director, Translational Medicine Expert in
Neuroscience with Novartis Pharma. Prior to Novartis, Dr. Garren
served as Co-Founder, Executive Vice President, Chief Scientific
Officer, and Chief Operating Officer of Bayhill Therapeutics, Inc.,
a company he started in 2002 based on a technology platform he
co-invented while at Stanford University.
Dr. Garren earned his Bachelor of Science from
the California Institute of Technology and his MD and PhD from the
University of California, Los Angeles (UCLA). He completed his
internship in internal medicine at UCLA, and his residency in
neurology and fellowship in neuroimmunology at Stanford
University.
About Prothena
Prothena Corporation plc is a late-stage
clinical company with expertise in protein dysregulation and a
pipeline of novel investigational therapeutics with the potential
to change the course of devastating rare peripheral amyloid and
neurodegenerative diseases. Fueled by its deep scientific expertise
built over decades of research, Prothena is advancing a pipeline of
therapeutic candidates for a number of indications and novel
targets for which its ability to integrate scientific insights
around neurological dysfunction and the biology of misfolded
proteins can be leveraged. Prothena’s pipeline includes both
wholly-owned and partnered programs being developed for the
potential treatment of diseases including AL amyloidosis, ATTR
amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number
of other neurodegenerative diseases.
Contacts:
MediaEllen Rose, Head of
Communications650-922-2405, ellen.rose@prothena.com
InvestorsJennifer Zibuda,
Director, Investor Relations & Communications650-837-8535,
jennifer.zibuda@prothena.com
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Prothena Corp. Plc - Ordinary Shares (MM) (NASDAQ:PRTAV)
Historical Stock Chart
From Jul 2023 to Jul 2024